|
US5081227A
(en)
|
1988-03-04 |
1992-01-14 |
La Jolla Cancer Research Foundation |
Germ cell alkaline phosphatase
|
|
ES2075169T3
(es)
*
|
1989-11-17 |
1995-10-01 |
Unilever Nv |
Agentes de union especifica.
|
|
US6773669B1
(en)
|
1995-03-10 |
2004-08-10 |
Maxcyte, Inc. |
Flow electroporation chamber and method
|
|
US6090617A
(en)
|
1996-12-05 |
2000-07-18 |
Entremed, Inc. |
Flow electroporation chamber with electrodes having a crystalline metal nitride coating
|
|
US20020004490A1
(en)
|
1999-04-12 |
2002-01-10 |
Dean Nicholas M. |
Antisense modulation of Fas mediated signaling
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
GB9827152D0
(en)
|
1998-07-03 |
1999-02-03 |
Devgen Nv |
Characterisation of gene function using double stranded rna inhibition
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
CA2361201A1
(en)
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
EP2011801A1
(en)
|
1999-05-27 |
2009-01-07 |
Government of the United States as represented by the Secretary, Department of Health and Human Services |
Immunoconjugates having high binding affinity
|
|
HK1047109A1
(zh)
|
1999-10-15 |
2003-02-07 |
University Of Massachusetts |
作为指定基因干预工具的rna干预轨迹基因
|
|
GB9927444D0
(en)
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
|
US8202846B2
(en)
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
|
CA2407695C
(en)
|
2000-04-28 |
2015-03-31 |
Sangamo Biosciences, Inc. |
Methods for binding an exogenous molecule to cellular chromatin
|
|
US7029916B2
(en)
|
2001-02-21 |
2006-04-18 |
Maxcyte, Inc. |
Apparatus and method for flow electroporation of biological samples
|
|
CN1302115C
(zh)
|
2001-04-23 |
2007-02-28 |
埃麦克萨有限公司 |
电穿孔用缓冲溶液及上述溶液的使用方法
|
|
KR100385905B1
(ko)
|
2001-05-17 |
2003-06-02 |
주식회사 웰진 |
유니진 유래의 안티센스 분자로 구성된 안티센스 라이브러리를 이용한 대규모 유전자 검색 및 기능 분석 방법
|
|
US6485974B1
(en)
|
2001-05-18 |
2002-11-26 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTPN2 expression
|
|
AU2002326717A1
(en)
|
2001-08-22 |
2003-03-10 |
Maxcyte, Inc. |
Apparatus and method for electroporation of biological samples
|
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
|
GB0124391D0
(en)
|
2001-10-11 |
2001-11-28 |
Gene Expression Technologies L |
Control of gene expression
|
|
US20050136040A1
(en)
|
2001-10-11 |
2005-06-23 |
Imperial College Innovations Limited |
Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
|
|
AU2002343792A1
(en)
|
2001-11-28 |
2003-06-10 |
Center For Advanced Science And Technology Incubation, Ltd. |
siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
|
|
WO2003080809A2
(en)
|
2002-03-21 |
2003-10-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
|
US7399586B2
(en)
|
2002-05-23 |
2008-07-15 |
Ceptyr, Inc. |
Modulation of biological signal transduction by RNA interference
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
WO2004030634A2
(en)
|
2002-10-02 |
2004-04-15 |
Alnylam Pharmaceuticals Inc. |
Therapeutic compositions
|
|
ITMI20030821A1
(it)
|
2003-04-18 |
2004-10-19 |
Internat Ct For Genetic En Gineering And |
Polipeptidi chimerici e loro uso.
|
|
US20060182736A1
(en)
|
2003-06-10 |
2006-08-17 |
Kim Jin-Soo |
Transducible dna-binding proteins
|
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
|
DE502004009820D1
(de)
|
2004-03-15 |
2009-09-10 |
Lonza Cologne Ag |
Behältnis und Vorrichtung zur Erzeugung von elektrischen Feldern in einzelnen Reaktionsräumen
|
|
US7771984B2
(en)
|
2004-05-12 |
2010-08-10 |
Maxcyte, Inc. |
Methods and devices related to a regulated flow electroporation chamber
|
|
JP4519915B2
(ja)
|
2004-06-12 |
2010-08-04 |
インビトロゲン シンガポール ピーティーイー．リミテッド． |
中空構造を有する電気穿孔装置
|
|
ES2465467T3
(es)
|
2004-06-14 |
2014-06-05 |
Lonza Cologne Ag |
Procedimiento y disposición de circuito para el tratamiento de material biológico
|
|
US20070254291A1
(en)
|
2004-06-14 |
2007-11-01 |
Xiaoxia Cui |
Gene Targeting in Eukaryotic Cells by Group II Intron Ribonucleoprotein Particles
|
|
US7991559B2
(en)
|
2004-11-30 |
2011-08-02 |
Maxcyte Inc. |
Computerized electroporation
|
|
EP1824872B1
(en)
|
2004-12-14 |
2012-02-08 |
Alnylam Pharmaceuticals Inc. |
Rnai modulation of mll-af4 and uses thereof
|
|
EP1885758A2
(en)
|
2005-05-12 |
2008-02-13 |
The Government of the United States of America as Represented by The Department of Health and Human Services |
Anti-mesothelin antibodies useful for immunological assays
|
|
CA2611861C
(en)
|
2005-06-08 |
2017-11-28 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for the treatment of persistent infections
|
|
US10022457B2
(en)
|
2005-08-05 |
2018-07-17 |
Gholam A. Peyman |
Methods to regulate polarization and enhance function of cells
|
|
DK2341149T3
(en)
|
2005-08-26 |
2017-02-27 |
Dupont Nutrition Biosci Aps |
Use of CRISPR-associated genes (Cas)
|
|
US20070161031A1
(en)
|
2005-12-16 |
2007-07-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Functional arrays for high throughput characterization of gene expression regulatory elements
|
|
BRPI0716427A2
(pt)
|
2006-08-11 |
2014-03-11 |
Dow Agrosciences Llc |
Recombinação homóloga mediada por nuclease de apêndice de zinco
|
|
US8252526B2
(en)
|
2006-11-09 |
2012-08-28 |
Gradalis, Inc. |
ShRNA molecules and methods of use thereof
|
|
US10155038B2
(en)
|
2007-02-02 |
2018-12-18 |
Yale University |
Cells prepared by transient transfection and methods of use thereof
|
|
WO2008109532A2
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting fas gene expression and uses thereof
|
|
US20100105134A1
(en)
|
2007-03-02 |
2010-04-29 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting gene expression and uses thereof
|
|
US8450112B2
(en)
|
2008-04-09 |
2013-05-28 |
Maxcyte, Inc. |
Engineering and delivery of therapeutic compositions of freshly isolated cells
|
|
US20120088842A1
(en)
|
2008-07-18 |
2012-04-12 |
Maxcyte, Inc. |
Methods for optimizing electroporation
|
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
|
EP2424877A4
(en)
|
2009-04-28 |
2013-01-02 |
Harvard College |
SUPRAGELADENE PROTEINS FOR CELL PENETRATION
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
WO2011072246A2
(en)
|
2009-12-10 |
2011-06-16 |
Regents Of The University Of Minnesota |
Tal effector-mediated dna modification
|
|
WO2011104382A1
(en)
|
2010-02-26 |
2011-09-01 |
Cellectis |
Use of endonucleases for inserting transgenes into safe harbor loci
|
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US9987308B2
(en)
|
2011-03-23 |
2018-06-05 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
US10391126B2
(en)
|
2011-11-18 |
2019-08-27 |
Board Of Regents, The University Of Texas System |
CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
WO2013126729A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Use of the cd2 signaling domain in second-generation chimeric antigen receptors
|
|
EP2817330B1
(en)
|
2012-02-22 |
2020-07-08 |
The Trustees of the University of Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
|
CA3285826A1
(en)
|
2012-02-22 |
2026-03-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
US20130236504A1
(en)
|
2012-03-06 |
2013-09-12 |
Medical University Of South Carolina |
Delivery System for Enhancing Drug Efficacy
|
|
EP2828290B1
(en)
|
2012-03-23 |
2018-08-15 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
JP6482461B2
(ja)
|
2012-07-13 |
2019-03-13 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
投与に関する形質導入ｔ細胞の適合性の評価方法
|
|
JP2015524255A
(ja)
|
2012-07-13 |
2015-08-24 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
|
|
BR122020002986A8
(pt)
|
2012-08-20 |
2023-04-18 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Método e composições para imunoterapia celular
|
|
EP3327037B1
(en)
|
2012-08-21 |
2019-10-09 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
CN104955845B
(zh)
|
2012-09-27 |
2018-11-16 |
美国政府(由卫生和人类服务部的部长所代表) |
间皮素抗体和引起有效的抗肿瘤活性的方法
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
AU2013335451C1
(en)
|
2012-10-23 |
2024-07-04 |
Toolgen Incorporated |
Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
|
|
US20160002626A1
(en)
|
2012-11-28 |
2016-01-07 |
Youwen Zhou |
Tox inhibition for the treatment of cancer
|
|
US9255250B2
(en)
|
2012-12-05 |
2016-02-09 |
Sangamo Bioscience, Inc. |
Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
|
|
PL3360964T3
(pl)
|
2012-12-06 |
2020-03-31 |
Sigma-Aldrich Co. Llc |
Modyfikacja i regulacja genomu oparta na crispr
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
EP2840140B2
(en)
|
2012-12-12 |
2023-02-22 |
The Broad Institute, Inc. |
Crispr-Cas based method for mutation of prokaryotic cells
|
|
DK2931891T3
(da)
|
2012-12-17 |
2019-08-19 |
Harvard College |
Rna-styret modificering af menneskelige genomer
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
CN113005091A
(zh)
|
2013-02-06 |
2021-06-22 |
细胞基因公司 |
具有改进特异性的修饰的t淋巴细胞
|
|
WO2014124267A1
(en)
|
2013-02-07 |
2014-08-14 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
|
|
DK2956175T3
(da)
|
2013-02-15 |
2017-11-27 |
Univ California |
Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
|
|
EP3628322A1
(en)
|
2013-03-01 |
2020-04-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer
|
|
WO2014164554A1
(en)
|
2013-03-10 |
2014-10-09 |
Baylor College Of Medicine |
Chemotherapy-resistant immune cells
|
|
EP2970985A1
(en)
|
2013-03-14 |
2016-01-20 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
CN112301024A
(zh)
|
2013-03-15 |
2021-02-02 |
通用医疗公司 |
使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
|
|
US9937207B2
(en)
|
2013-03-21 |
2018-04-10 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell receptor genes using talens
|
|
CA2908403A1
(en)
|
2013-04-02 |
2014-10-09 |
Bayer Cropscience Nv |
Targeted genome engineering in eukaryotes
|
|
WO2014165707A2
(en)
|
2013-04-03 |
2014-10-09 |
Memorial Sloan-Kettering Cancer Center |
Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
|
|
EP3783098A1
(en)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
|
WO2014191128A1
(en)
|
2013-05-29 |
2014-12-04 |
Cellectis |
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
|
|
CA3051222C
(en)
|
2013-06-10 |
2023-01-24 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for reducing immunosupression by tumor cells
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
WO2015048690A1
(en)
|
2013-09-27 |
2015-04-02 |
The Regents Of The University Of California |
Optimized small guide rnas and methods of use
|
|
EP3441468B1
(en)
|
2013-10-17 |
2021-05-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
CA2930590C
(en)
|
2013-11-15 |
2021-02-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineering neural stem cells using homologous recombination
|
|
US10787684B2
(en)
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
|
JP7103750B2
(ja)
|
2013-12-12 |
2022-07-20 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
|
|
EP3470089A1
(en)
|
2013-12-12 |
2019-04-17 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
JP6712948B2
(ja)
|
2013-12-12 |
2020-06-24 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
|
|
US20160304893A1
(en)
|
2013-12-13 |
2016-10-20 |
Cellectis |
Cas9 nuclease platform for microalgae genome engineering
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
WO2015092024A2
(en)
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
EP3099801B1
(en)
|
2014-01-31 |
2020-03-18 |
Factor Bioscience Inc. |
Synthetic rna for use in the treatment of dystrophic epidermolysis bullosa
|
|
WO2015115903A1
(en)
|
2014-02-03 |
2015-08-06 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Site-specific dna break-induced genome editing using engineered nucleases
|
|
CA2939711C
(en)
|
2014-02-21 |
2020-09-29 |
Cellectis |
Method for in situ inhibition of regulatory t cells
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
US10611837B2
(en)
|
2014-04-10 |
2020-04-07 |
Seattle Children's Hospital |
Transgene genetic tags and methods of use
|
|
WO2015161276A2
(en)
|
2014-04-18 |
2015-10-22 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
EP3154555A4
(en)
|
2014-06-10 |
2018-02-28 |
Monash University |
Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
|
|
EP3188763B1
(en)
|
2014-09-02 |
2020-05-13 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification
|
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
|
US9879283B2
(en)
|
2014-10-09 |
2018-01-30 |
Life Technologies Corporation |
CRISPR oligonucleotides and gene editing
|
|
US20170335331A1
(en)
|
2014-10-31 |
2017-11-23 |
The Trustees Of The University Of Pennsylvania |
Altering Gene Expression in CART Cells and Uses Thereof
|
|
WO2016097751A1
(en)
|
2014-12-18 |
2016-06-23 |
The University Of Bath |
Method of cas9 mediated genome engineering
|
|
JP2018509387A
(ja)
|
2015-01-21 |
2018-04-05 |
フェーズアールエックス インコーポレイテッド |
細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
|
|
WO2016118857A1
(en)
|
2015-01-23 |
2016-07-28 |
Musc Foundation For Research Development |
Cytokine receptor genes and the use thereof to enhance therapy
|
|
WO2016123578A1
(en)
|
2015-01-30 |
2016-08-04 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016135559A2
(en)
|
2015-02-23 |
2016-09-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
|
KR102624023B1
(ko)
|
2015-02-24 |
2024-01-11 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
결합-촉발된 전사 스위치 및 이들의 이용 방법
|
|
CN107614012A
(zh)
|
2015-04-24 |
2018-01-19 |
加利福尼亚大学董事会 |
使用工程化的细胞检测、监测或治疗疾病或病况的系统及制备和使用它们的方法
|
|
US20160361415A1
(en)
|
2015-05-28 |
2016-12-15 |
Armo Biosciences, Inc. |
Methods of Using Interleukin-10 for Treating Diseases and Disorders
|
|
KR102349677B1
(ko)
|
2015-05-28 |
2022-01-12 |
카이트 파마 인코포레이티드 |
T 세포 요법을 위해 환자를 컨디셔닝하는 방법
|
|
WO2016196388A1
(en)
|
2015-05-29 |
2016-12-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
JP2018518182A
(ja)
|
2015-06-17 |
2018-07-12 |
ザ ユーエービー リサーチ ファンデーション |
ゲノム編集のためのｃｒｉｓｐｒ／ｃａｓ９複合体
|
|
JP2018518181A
(ja)
|
2015-06-17 |
2018-07-12 |
ザ ユーエービー リサーチ ファンデーション |
血液細胞系列の細胞に機能的ポリペプチドを導入するためのＣＲＩＳＰＲ／Ｃａｓ９複合体
|
|
JP7033453B2
(ja)
|
2015-06-30 |
2022-03-10 |
セレクティス |
特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法
|
|
US20170000743A1
(en)
|
2015-07-02 |
2017-01-05 |
Vindico NanoBio Technology Inc. |
Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
|
|
AU2016291778B2
(en)
|
2015-07-13 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
US10093717B2
(en)
|
2015-08-07 |
2018-10-09 |
Shenzhen In Vivo Biomedicine Technology Limited Company |
Chimeric antigen receptor containing a toll-like receptor intracellular domain
|
|
MX2018002043A
(es)
|
2015-08-17 |
2018-07-06 |
Janssen Pharmaceutica Nv |
ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US20180243446A1
(en)
|
2015-09-01 |
2018-08-30 |
The Hospital For Sick Children |
Method and compositions for removing duplicated copy number variaions (cnvs) for genetic disorders and related uses
|
|
AU2016323985B2
(en)
*
|
2015-09-17 |
2022-12-15 |
Novartis Ag |
CAR T cell therapies with enhanced efficacy
|
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
|
EP3356533A1
(en)
|
2015-09-28 |
2018-08-08 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
|
JP6816133B2
(ja)
|
2015-10-05 |
2021-01-20 |
プレシジョン バイオサイエンシズ，インク． |
改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
|
|
US20180327706A1
(en)
|
2015-10-19 |
2018-11-15 |
The Methodist Hospital |
Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation
|
|
EP3365454A1
(en)
|
2015-10-20 |
2018-08-29 |
10X Genomics, Inc. |
Methods and systems for high throughput single cell genetic manipulation
|
|
WO2017070429A1
(en)
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
|
KR20250141836A
(ko)
|
2015-11-04 |
2025-09-29 |
페이트 세러퓨틱스, 인코포레이티드 |
만능 세포의 유전자 조작
|
|
CA3005968A1
(en)
|
2015-11-23 |
2017-06-01 |
The Regents Of The University Of California |
Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
|
|
SI3383920T1
(sl)
|
2015-11-30 |
2024-06-28 |
The Regents Of The University Of California |
Dostava tumorsko specifičnega koristnega tovora in imunska aktivacija z uporabo humanega protitelesa, ki cilja visoko specifičen površinski antigen tumorskih celic
|
|
EP3389677B1
(en)
|
2015-12-18 |
2024-06-26 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the t cell receptor
|
|
CA3009715A1
(en)
|
2015-12-30 |
2017-07-06 |
Avectas Limited |
Vector-free delivery of gene editing proteins and compositions to cells and tissues
|
|
JP2019509738A
(ja)
|
2016-03-11 |
2019-04-11 |
ブルーバード バイオ， インコーポレイテッド |
ゲノム編集された免疫エフェクター細胞
|
|
US20170267755A1
(en)
|
2016-03-16 |
2017-09-21 |
Sri International |
Isolated anti-mesothelin antibodies, conjugates and uses thereof
|
|
US20190161530A1
(en)
|
2016-04-07 |
2019-05-30 |
Bluebird Bio, Inc. |
Chimeric antigen receptor t cell compositions
|
|
EP4711465A2
(en)
|
2016-04-14 |
2026-03-18 |
Fred Hutchinson Cancer Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
EP4628587A3
(en)
|
2016-04-15 |
2026-02-25 |
Memorial Sloan Kettering Cancer Center |
Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
|
|
US11499168B2
(en)
|
2016-04-25 |
2022-11-15 |
Universitat Basel |
Allele editing and applications thereof
|
|
WO2017189336A1
(en)
|
2016-04-25 |
2017-11-02 |
The Regents Of The University Of California |
Methods and compositions for genomic editing
|
|
EP4166660A1
(en)
|
2016-04-29 |
2023-04-19 |
BASF Plant Science Company GmbH |
Improved methods for modification of target nucleic acids using fused guide rna - donor molecules
|
|
US20190136230A1
(en)
|
2016-05-06 |
2019-05-09 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
|
US20190136224A1
(en)
|
2016-05-31 |
2019-05-09 |
Massachusetts Institute Of Technology |
Hydrodynamically Controlled Electric Fields for High Throughput Transformation & High Throughput Parallel Transformation Platform
|
|
EP3472338B1
(en)
|
2016-06-20 |
2024-05-22 |
Octapharma AG |
Means and methods for modifying multiple alleles
|
|
US20170362635A1
(en)
|
2016-06-20 |
2017-12-21 |
University Of Washington |
Muscle-specific crispr/cas9 editing of genes
|
|
AU2017286835B2
(en)
|
2016-06-29 |
2023-12-14 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
|
AU2017291851B2
(en)
|
2016-07-06 |
2022-10-13 |
Cellectis |
Sequential gene editing in primary immune cells
|
|
WO2018035387A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
US11999931B2
(en)
|
2016-08-20 |
2024-06-04 |
The Regents Of The University Of California |
High-throughput system and method for the temporary permeabilization of cells
|
|
CN109843929B
(zh)
|
2016-08-23 |
2024-07-05 |
加利福尼亚大学董事会 |
蛋白水解可切割的嵌合多肽及其使用方法
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
US20180127786A1
(en)
|
2016-09-23 |
2018-05-10 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for gene editing
|
|
WO2018067993A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
CN110291100B
(zh)
|
2016-10-12 |
2024-06-11 |
费尔丹生物公司 |
用于将多肽负荷从细胞外空间递送至靶真核细胞的胞质溶胶和/或细胞核的合理设计的合成肽穿梭剂，其用途、与其相关的方法和试剂盒
|
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
WO2018094291A1
(en)
|
2016-11-18 |
2018-05-24 |
Christopher Bradley |
Massively multiplexed homologous template repair for whole-genome replacement
|
|
AU2017378427A1
(en)
|
2016-12-14 |
2019-06-20 |
Ligandal, Inc. |
Methods and compositions for nucleic acid and protein payload delivery
|
|
EP3565830B1
(en)
|
2017-01-09 |
2021-03-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
|
JP7235391B2
(ja)
|
2017-05-08 |
2023-03-08 |
ツールゲン インコーポレイテッド |
人工的に操作された免疫細胞
|
|
US10858443B2
(en)
|
2017-05-31 |
2020-12-08 |
Trustees Of Boston University |
Synthetic notch protein for modulating gene expression
|
|
WO2018232356A1
(en)
|
2017-06-15 |
2018-12-20 |
The Regents Of The University Of California |
Targeted non-viral dna insertions
|
|
WO2019079034A1
(en)
|
2017-10-17 |
2019-04-25 |
The General Hospital Corporation |
METHODS AND COMPOSITIONS RELATING TO GENETICALLY MODIFIED REGULATORY T LYMPHOCYTES
|
|
JP7101419B2
(ja)
|
2017-10-27 |
2022-07-15 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
内因性ｔ細胞受容体の標的置換
|
|
JP2021501156A
(ja)
|
2017-10-27 |
2021-01-14 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Ｔ細胞疲弊を予防および逆転するためのエピジェネティック標的および転写標的の同定
|
|
EP3714042A4
(en)
|
2017-11-22 |
2021-08-04 |
La Jolla Institute for Allergy and Immunology |
USE AND PRODUCTION OF MODIFIED IMMUNE CELLS
|
|
EP3737765B2
(en)
|
2018-01-12 |
2025-01-22 |
Curocell Inc. |
Enhanced immune cells using dual shrna and composition including the same
|
|
US20200399383A1
(en)
*
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
WO2019164979A1
(en)
*
|
2018-02-21 |
2019-08-29 |
Cell Design Labs, Inc. |
Chimeric transmembrane receptors and uses thereof
|
|
MA52116A
(fr)
|
2018-03-02 |
2021-01-06 |
Generation Bio Co |
Vecteurs d'adn à extrémité fermée (cedna) pour l'insertion de transgènes au niveau de havres génomiques sécuritaires (gsh) dans des génomes humains et murins
|
|
CN112041433A
(zh)
|
2018-03-15 |
2020-12-04 |
Ksq治疗公司 |
用于改进的免疫疗法的基因调控组合物和方法
|
|
US20210207174A1
(en)
|
2018-05-25 |
2021-07-08 |
The Regents Of The University Of California |
Genetic engineering of endogenous proteins
|
|
CN112601546B
(zh)
|
2018-06-12 |
2024-04-16 |
湖南远泰生物技术有限公司 |
Plap-car-效应细胞
|
|
WO2020014235A1
(en)
|
2018-07-09 |
2020-01-16 |
The Regents Of The University Of California |
Gene targets for t-cell-based immunotherapy
|
|
US20220081691A1
(en)
|
2018-08-07 |
2022-03-17 |
Dana-Farber Cancer Institute, Inc |
Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
|
|
CA3111087A1
(en)
|
2018-08-29 |
2020-03-05 |
Nanjing Legend Biotech Co., Ltd. |
Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
|
|
CN110904045A
(zh)
|
2018-09-17 |
2020-03-24 |
中国科学院动物研究所 |
经修饰的t细胞、其制备方法及用途
|
|
WO2020072125A1
(en)
|
2018-10-03 |
2020-04-09 |
Massachusetts Institute Of Technology |
Splicing-dependent transcriptional gene silencing or activation
|
|
MX2021006208A
(es)
|
2018-11-28 |
2021-10-01 |
Univ Texas |
Edición por multiplexación del genoma de células inmunitarias para mejorar la funcionalidad y resistencia al entorno supresor.
|
|
US12359179B2
(en)
|
2018-12-12 |
2025-07-15 |
The Regents Of The University Of California |
Compositions and methods for modifying a target nucleic acid
|
|
AU2019406186A1
(en)
|
2018-12-20 |
2021-07-15 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of KCNT1 related disorders
|
|
EP3911735A4
(en)
|
2019-01-16 |
2023-07-12 |
Beam Therapeutics, Inc. |
MODIFIED IMMUNE CELLS WITH INCREASED ANTINEOPLASTIC ACTIVITY AND RESISTANCE TO IMMUNOSUPPRESSION
|
|
CN113396216A
(zh)
|
2019-02-04 |
2021-09-14 |
Ksq治疗公司 |
用于改进的免疫疗法的组合基因靶标
|
|
CN113840920A
(zh)
|
2019-03-14 |
2021-12-24 |
加利福尼亚大学董事会 |
合并的敲入筛选和在内源基因座控制下共表达的异源多肽
|
|
US20220226380A1
(en)
|
2019-04-24 |
2022-07-21 |
St. Jude Children's Research Hospital, Inc. |
Gene knock-outs to improve t cell function
|
|
EP3963076A1
(en)
|
2019-05-02 |
2022-03-09 |
Celyad |
Cells with multiplexed inhibitory rna
|
|
US11162102B2
(en)
*
|
2019-05-13 |
2021-11-02 |
Dna Twopointo Inc. |
Modifications of mammalian cells using artificial micro-RNA to alter their properties and the compositions of their products
|
|
WO2021044373A2
(en)
*
|
2019-09-06 |
2021-03-11 |
Avectas Limited |
Engineering of immune cells for ex vivo cell therapy applications
|
|
DE102019214466A1
(de)
|
2019-09-23 |
2021-03-25 |
Henkel Ag & Co. Kgaa |
Mittel zum Färben von keratinischem Material mit Aminosilikon, farbgebender Verbindung und ethoxyliertem Fettsäureester
|
|
AU2020355031A1
(en)
|
2019-09-24 |
2022-05-19 |
The Regents Of The University Of California |
Notch receptors with hinge domain
|
|
EP4034553A4
(en)
|
2019-09-24 |
2023-10-11 |
Regents of the University of California |
NOVEL RECEPTORS FOR LIGAND-DEPENDENT TRANSCRIPTIONAL REGULATION
|
|
EP4034251A4
(en)
|
2019-09-24 |
2023-11-08 |
The Regents of the University of California |
Novel receptors having a heterologous stop transfer sequence for ligand-dependent transcriptional regulation
|
|
EP4034138A4
(en)
|
2019-09-27 |
2024-07-31 |
Beam Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
|
|
AU2020388690A1
(en)
|
2019-11-20 |
2022-06-09 |
Cartherics Pty. Ltd. |
Method for providing immune cells with enhanced function
|
|
CA3163258A1
(en)
|
2019-11-27 |
2021-06-03 |
Board Of Regents, The University Of Texas System |
Large-scale combined car transduction and crispr gene editing of nk cells
|
|
CN115003314A
(zh)
|
2019-11-27 |
2022-09-02 |
得克萨斯大学体系董事会 |
B细胞的大规模组合car转导和crispr基因编辑
|
|
US20230045174A1
(en)
|
2019-11-27 |
2023-02-09 |
Board Of Regents, The University Of Texas System |
Large-scale combined car transduction and crispr gene editing of msc cells
|
|
WO2021154534A1
(en)
|
2020-01-28 |
2021-08-05 |
Promab Biotechnologies, Inc. |
Plap-cd3 epsilon bispecific antibodies
|
|
JP7789002B2
(ja)
|
2020-01-29 |
2025-12-19 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
|
|
CN115666726A
(zh)
|
2020-04-09 |
2023-01-31 |
加利福尼亚大学董事会 |
具有铰链结构域的人源化Notch受体
|
|
MX2023004822A
(es)
|
2020-10-26 |
2023-05-10 |
Arsenal Biosciences Inc |
Loci de puerto seguro.
|
|
US11332744B1
(en)
|
2020-10-26 |
2022-05-17 |
Arsenal Biosciences, Inc. |
Safe harbor loci
|
|
WO2022150831A1
(en)
|
2021-01-07 |
2022-07-14 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Car cells and polyspecific binding molecules for treating solid tumor
|
|
US20220235380A1
(en)
*
|
2021-01-26 |
2022-07-28 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed shrnas and logic gate systems
|
|
US12592129B2
(en)
|
2021-10-05 |
2026-03-31 |
Aristocrat Technologies, Inc. |
Electronic gaming machine with symbols streaming adjacent an active reel matrix with reel expansion and symbol absorption processes
|
|
MX2024004550A
(es)
|
2021-10-14 |
2024-04-29 |
Teneobio Inc |
Proteinas de union a la mesotelina y usos de las mismas.
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|